Wyost's Official Entry into the European Market

Sandoz (SDZ), a Swiss global biosimilar specialist, has received final marketing authorization from the European Commission (EC) for Wyost, its denosumab biosimilar. This approval follows the U.S. Food and Drug Administration (FDA)'s approval of Wyost as an interchangeable biosimilar in March 2024, marking a significant achievement. It signifies the commencement of commercialization in Europe, one of the largest markets globally. The regulatory authority's decision confirms that Wyost demonstrates comparable efficacy and safety across all indications when compared to the reference product, including the prevention of skeletal-related events (SREs) in patients with bone metastases from solid tumors. Consequently, Sandoz will have a powerful tool to replace the originator drug in oncology and surgery fields throughout Europe.

Competitive Landscape with the Originator Drug, Xgeva

The reference product for Wyost is Xgeva, a blockbuster drug from Amgen (AMGN). Xgeva is a monoclonal antibody that targets RANKL (Receptor Activator of Nuclear Factor-kappa B Ligand), a protein that promotes osteoclast activation, thereby inhibiting bone resorption. In patients with solid tumors with bone metastases, Xgeva has been a standard of care for preventing severe skeletal complications such as fractures and spinal cord compression. With the launch of Wyost, Sandoz is expected to significantly reduce the financial burden on patients by offering a more affordable alternative to the originator drug, thereby improving treatment access in the European market.

Demonstrated Bioequivalence through Phase 3 Clinical Data

The scientific basis for this approval is the results of the ROSALIA (NCT03974100) clinical trial, a large-scale, multinational Phase 1/3 integrated study. In the 52-week clinical trial, the Wyost group showed a mean change from baseline in lumbar spine bone mineral density (BMD) of 4.89%, while the originator denosumab group showed 4.55%. The difference in efficacy between the two groups was 0.34% (95% confidence interval: -0.40, 1.09), which fully met the pre-defined statistical equivalence margin. No clinically significant differences were observed in pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, or safety profiles, providing strong clinical evidence for interchangeability.

Reshaping the $4 Billion Denosumab Market

The global denosumab market is estimated at approximately $3.67 billion in 2025 and is projected to exceed $4.06 billion in 2026. Amgen, the originator, has experienced significant market erosion due to patent expiration and biosimilar competition, with combined sales of Prolia and Xgeva declining by 32% year-over-year to $1.1 billion in the first quarter of 2026. Sandoz, with its established distribution network in the global pharmaceutical market, is expected to rapidly gain market share with the early market launch of Wyost. The introduction of an affordable biosimilar aligns perfectly with the policy objectives of European governments to improve the sustainability of national healthcare budgets, and rapid growth is expected.

Challenges in European Pricing Negotiations and Reimbursement

Following the marketing authorization, Wyost's commercial success will depend on the timely completion of pricing negotiations with individual European countries and reimbursement procedures by healthcare authorities. The European market has varying healthcare reimbursement systems and biosimilar preferential policies, making a customized market entry strategy essential for each key country. Furthermore, Sandoz must strategically manage the legal risks associated with patent disputes that Amgen may initiate to defend its patent portfolio and coordinate the launch schedule. If Sandoz overcomes these initial hurdles in market entry, it is expected to diversify its oncology biosimilar portfolio and strengthen its long-term revenue pipeline.